We have developed a unique regulatory expertise when it comes to Live Biotherapeutics. This new class of medicines is brand new both for companies and regulators, and thus require close interactions and specific know-how.
Our work on EXL01 has empowered us to advance new programs in record times, through optimized regulatory tracks.
